Intuitive Surgical stock price target raised to $625 by RBC on strong Q3

Investing.com - RBC Capital has raised its price target on Intuitive Surgical (NASDAQ:ISRG), a $165.9 billion market cap medical robotics leader, to $625 from $615 while maintaining an Outperform rating following the company’s strong third-quarter performance. According to InvestingPro analysis, the stock is currently trading above its Fair Value.

The surgical robotics company delivered results that exceeded expectations, with sales and earnings per share beating forecasts by 4% and 20% respectively, according to RBC Capital.

Intuitive Surgical’s stock jumped 17% in after-hours trading, driven by positive placements of its total and da Vinci 5 surgical systems, increased procedure volume, and the significant earnings beat.

RBC Capital noted that the third-quarter report helped address investor concerns regarding da Vinci 5 adoption, the hospital environment, and re-manufacturers.

The investment firm expressed bullishness on Intuitive’s prospects, highlighting that the third quarter of 2025 marks the beginning of a trade-in and multi-year replacement cycle for the company, with da Vinci 5 placements expected to accelerate into 2026.

In other recent news, Intuitive Surgical has reported several notable developments. The company received U.S. Food and Drug Administration clearance for software advancements in its Ion endoluminal system, introducing artificial intelligence to enhance lung biopsy procedures. This update integrates advanced imaging capabilities, marking a significant step in the system’s navigational workflow. Analyst firms have also weighed in on Intuitive Surgical’s prospects. Evercore ISI raised its price target for the company to $540, citing strong performance and exceeding expectations in system placements and procedure utilization. Bernstein SocGen Group reiterated an Outperform rating with a price target of $685, pointing to the potential upside in the company’s third-quarter results. Meanwhile, Piper Sandler reaffirmed its Overweight rating with a $595 price target after meeting with key executives from Intuitive Surgical. These developments indicate a strong interest from analysts in the company’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.